J Korean Ophthalmol Soc > Volume 57(6); 2016 > Article
Journal of the Korean Ophthalmological Society 2016;57(6):930-934.
DOI: https://doi.org/10.3341/jkos.2016.57.6.930    Published online June 15, 2016.
Relationship between Pain and Injection Site during Intravitreal Injection.
Kyeong Do Jeong, Jung Hoon Kim, Jae Suk Kim, Je Hyung Hwang
Department of Ophthalmology, Inje University Sanggye Paik Hospital, Seoul, Korea. violentviolet15@daum.net
유리체강 내 주사 시 주사 방향에 따른 통증 차이
정경도⋅김정훈⋅김재석⋅황제형
인제대학교 상계백병원 안과학교실
Correspondence:  Je Hyung Hwang,
Email: violentviolet15@daum.net
Received: 17 March 2016   • Revised: 8 April 2016   • Accepted: 9 May 2016
Abstract
PURPOSE
Using a visual analogue scale, patients pain was compared according to injection site during intravitreal injection. METHODS: A prospective, clinical trial was conducted on 171 eyes of patients experiencing age-related macular degeneration, diabetic retinopathy, retinal vein occlusion, or central serous chorioretinopathy. After determining the anatomic quadrant of the injection site, patients were randomized to receive intravitreal bevacizumab, aflibercept, ranibizumab, or dexamethasone injection. Fifteen minutes after the injection, patients completed a survey about pain using a visual analogue scale from 0 (no pain) to 10 (unbearable pain). RESULTS: According to the visual analogue scale, pain score was 3.20 at the superotemporal site, 3.03 at the superonasal site, and 2.35 at the inferonasal site. Pain was lowest when injected in an inferotemporal site (p = 0.012). CONCLUSIONS: Intravitreal injection at an inferotemporal site can help reduce patient pain.
Key Words: Intravitreal injection;Pain measurement;Visual analogue scale


ABOUT
BROWSE ARTICLES
EDITORIAL POLICY
FOR CONTRIBUTORS
Editorial Office
SKY 1004 Building #701
50-1 Jungnim-ro, Jung-gu, Seoul 04508, Korea
Tel: +82-2-583-6520    Fax: +82-2-583-6521    E-mail: kos08@ophthalmology.org                

Copyright © 2022 by Korean Ophthalmological Society.

Developed in M2PI

Close layer
prev next